Concepedia
Statistics
Publications
5
Citations
408
H-Index
Active since
2014
Affiliations
Novartis (United Kingdom)(Current)
GW Pharmaceuticals (United Kingdom)
Luke Bevan is an author at Novartis (United Kingdom) specializing in pharmacology, cell signaling, and molecular oncology.
Publications per year
2014–2021
Notch2 Is Required for Inflammatory Cytokine-Driven Goblet Cell Metaplasia in the Lung
Henry Danahay, Angelica D. Pessotti, Julie Coote et al. · Cell Reports · 2014 · 257 citations · Full text
Life Sciences, Cell Biology, Developmental Biology +17
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction
Gianni Chessari, Ian R. Hardcastle, Jong Sook Ahn et al. · Journal of Medicinal Chemistry · 2021 · 53 citations
Pharmacy, Medicinal Chemistry, Pharmacology +12
3D Reconstruction of the Human Airway Mucosa In Vitro as an Experimental Model to Study NTHi Infections
Pasquale Marrazzo, Silvia Maccari, Annarita Taddei et al. · PLoS ONE · 2016 · 45 citations · Full text
Life Sciences, Infectious Diseases, Microbiology +17
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Joanne M. Munck, Valério Berdini, Luke Bevan et al. · Molecular Cancer Therapeutics · 2021 · 34 citations · Full text
Medicine, Oncology, Pharmacology +17
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D. Heightman, Valério Berdini, Luke Bevan et al. · Journal of Medicinal Chemistry · 2021 · 19 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +14
1–5 of 5